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Toll-like receptor (TLR) signaling has been implicated in the inflammatory responses in
intestinal epithelial cells (IECs). Such inflammatory signals mediate complex interactions
between commensal bacteria and TLRs and are required for IEC proliferation, immune
response, repair, and homeostasis. The upregulation of certain TLRs in colorectal cancer
(CRC) tissues suggests that TLRs may play an essential role in the prognosis of chronic
and inflammatory diseases that ultimately culminate in CRC. Here, we provide a compre-
hensive review of the literature on the involvement of the TLR pathway in the initiation,
progression, and metastasis of CRC, as well as inherited genetic variation and epigenetic
regulation. The differential expression of TLRs in epithelial cells has also been discussed.
In particular, we emphasize the physiological role of TLR4 in CRC development and patho-
genesis, and propose novel and promising approaches for CRC therapeutics with the aid
of TLR ligands.
Keywords: colorectal cancer, immune response, inflammation, ligand, toll-like receptor 4
INTRODUCTION
The innate immune system possesses a robust mechanism in the
form of evolutionarily conserved toll-like receptors (TLRs) that
can detect the signature pattern of invading microorganisms for
the protection of the host. TLRs are a class of type I trans-
membrane glycoproteins. Human and mouse cells comprises of 13
types of TLRs that can detect different kinds of bacterial and viral-
associated patterns (1–3). TLR1–9 are highly conserved in both
species; while the mouse TLR10 is non-functional due to retro-
viral insertion, TLR11–13 are undetected in the human genome.
Examples of TLR-specific ligands are: lipopeptides for TLR1/2 and
2/6 (4–6), dsRNA for TLR3 (7), lipopolysaccharide (LPS) for TLR4
(8), flagellin for TLR5 (9), ssRNA for TLR7/8 (10, 11), and CpG
DNA for TLR9 (12–14). TLRs not only detect invading microbes
but also recognize intracellular anomalies and mount an immune
response, thereby playing a cardinal role in the homeostasis of
the human immune system (15, 16). The abnormal activation of
TLRs can jeopardize normal physiological processes and cause
several inflammatory diseases, cancers, and autoimmune diseases
(17, 18).
Toll-like receptors are ubiquitously expressed, although their
expression level may vary according to the circumstances and
the tissues. In addition, induced expression of TLRs has been
observed when ligands bind to their cognate TLRs (19). Research
in the last decade has focused on elucidating various functions,
intermediate molecules, and ligands associated with TLRs. There
is a well-established link between TLR-induced inflammation and
the development and progression of cancer (20, 21). Similarly,
TLRs are also known to play a vital role in colorectal cancer (CRC)
that affects the large intestine and the rectum. This region is heavily
populated by intestinal microbes, highlighting the crucial role of
TLRs in CRC pathogenesis (17, 22).
Colorectal cancer is one of the most complex diseases and
causes death in many cases in the United States (23). Globally,
more than one million new cases of CRC are reported annually
(24, 25). The complexity of CRC is primarily attributed to envi-
ronmental factors, while genetic factors play a minor role. The
known risk factors for CRC are food-borne mutagens, pollution,
certain commensal bacteria, and chronic intestinal inflammation
(25). Commonly, CRC occurs in the right ascending colon with
the most common symptom being blood in the stool or rec-
tal bleeding. Genetically, inherited colon polyps also contribute
to the development of CRC (26). Since CRC can damage the
host immune system during their proliferation period, stimulat-
ing it against CRC promises to be an attractive approach for drug
discovery (27).
In this review, we discuss the role of TLRs in the maintenance
of homeostasis and the development of CRC in intestinal epithe-
lial cells (IECs). Improved techniques to detect dysfunctional
TLR signaling in carcinogenesis may stimulate the development
of novel therapies to prevent or treat CRC. Recent studies have
improved the understanding of TLR-targeted applications such
as identifying their differential expression, their role in tumor
progression, potential use as immune modulating agents, and
development of novel TLR ligands in anti-cancer therapies.
TLR SIGNALING: AN OVERVIEW
The localization of TLRs is heterogeneous and varies from the
cell surface (TLR1, 2, 4, 5, 6, 10, and mouse TLR11, 12) to
the endosomes (TLR3, 7, 8, and 9) (28), depending on the
localization of pathogen-associated molecular patterns (PAMPs).
TLRs comprises of the following three domains: ectodomain
[contains leucine rich repeats (LRR)] that recognizes PAMPs, a
trans-membrane region, and a cytosolic toll/interleukin-1 (IL-1)
www.frontiersin.org July 2014 | Volume 5 | Article 334 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yesudhas et al. Roles of TLR4 in CRC development
receptor (TIR) domain that interacts with adaptor molecules (such
as MyD88/MAL and TRIF/TRAM) to propagate downstream sig-
naling. Ligand binding triggers the dimerization of TLRs, facilitat-
ing the binding of adaptor molecules, which subsequently activate
the IL-1 receptor-associated kinase (IRAK) family (29). Upon
IRAK recruitment, IRAK4 phosphorylates IRAK1 at key serine
and threonine residues, and enables IRAK1 to eventually acti-
vate tumor necrosis factor receptor-associated factor 6 (TRAF6)
(30) that subsequently activates transforming growth factor-β-
activated protein kinase 1 (TAK1), a member of the mitogen-
activated protein (MAP) kinase kinase kinase (MAP3K) family.
TAK1 forms a complex with TGF-β-activated kinase 1/MAP3K7
binding protein 1 (TAB1), TAB2, and TAB3 and then activates
nuclear factor (NF)-κB by phosphorylating IKK that in turn
phosphorylates IκB for proteasomal degradation. Following the
degradation of IκB, NF-κB translocates into the nucleus and
induces inflammatory mediators. Moreover, TAK1 activates mem-
bers of the MAP kinase kinase 3 (MKK3) and MKK6 to activate
an alternative closely related pathway that phosphorylates c-Jun
N-terminal Kinase (JNK) and p38. TLR signaling can also acti-
vate extracellular signal-regulated kinase (ERK) via the activation
of MEK1/2. In response to various TLR ligands, reduced activity
of NF-κB, JNK, and p38 was observed in B cells and embry-
onic fibroblasts derived from TAK1-deficient mice (31). In the
TRIF-dependent pathway triggered by TLR3 and TLR4, TRIF
recruits TRAF3, TAB1, and IKK and activates the type I IFN. The
TRIF-dependent pathway also activates TRAF6 and TAB1, which
regulate the delayed activation of NF-κB and MAP kinases (32)
(Figure 1).
TLRs AND THEIR EXPRESSION PATTERNS IN IECs
The human intestinal tract plays a crucial role in maintaining
the complex ecosystem of commensal bacteria and also phys-
ically isolates the countless resident bacteria from the lamina
propria (33). It was originally believed that IECs prevent bacteria
from invading the body. However, IECs have a complicated and
common beneficial link with the microorganisms in the intesti-
nal gut flora. The commensal bacteria metabolize carbohydrates
and the IECs break down the short-chain fatty acids produced
as a result of bacterial fermentation of undigested carbohydrates
and use them as an energy source (34). IEC membranes express
TLRs that detect the commensal PAMPs and mediate signal-
ing to maintain epithelial cell integrity and tight junctions, cell
proliferation, immunoglobulin A (IgA) production, and antimi-
crobial peptide expression (34). In addition, they can also induce
a pro-inflammatory response by interacting with the immune
cells in the lamina propria (35, 36). Therefore, tight regulation
of TLRs is imperative to prevent adverse effects since anomalous
or dysregulated TLR signaling can mediate cancer induction and
propagation.
Colorectal cancer pathogenesis is governed by TLR expres-
sion that is difficult to detect due to the heterogeneous nature
of IECs (33). To elucidate the expression profile of TLR2–5 in
epithelial cells, small intestinal, and colonic biopsy specimens from
patients with inflammatory bowel disease (IBD) were assessed by
immunofluorescence histochemistry using polyclonal antibodies
against TLR2, 3, 4, and 5. This study showed that TLR3 and TLR5
are ubiquitously expressed while TLR2 and TLR4 are expressed
at a very low level in normal cells (37). Conversely, the dis-
eased tissue specimens demonstrated significant overexpression
of TLR4 and a decline in TLR3 expression. The expression pattern
of TLR2 and TLR5 remained unaltered between the normal and
diseased specimens. Furthermore, in normal human IECs, TLR2,
and TLR4 were marginally expressed, while TLR3 expression was
relatively high. While TLR2 was expressed in the colonic tissue
from the epithelium and lamina propria, TLR3 was expressed in
the mature epithelial cells of the crypts. Furthermore, TLR5 was
moderately overexpressed in a basolateral fashion in the epithelial
cells of normal human tissues (38). Tissues from CRC patients
demonstrated increased expression of TLR7, 8, 9, and 10 (39); this
study also showed that TLR8 expression is an independent marker
for CRC.
TLRs AND INTESTINAL HOMEOSTASIS
Toll-like receptor activation is responsible for fighting against
microbial infections, while leaving the host cell intact. This is usu-
ally accomplished by producing antimicrobial peptides, inflam-
matory mediators, adenomatous polyposis coli (APCs) matura-
tion, and triggering of cell survival and tissue repairing pathways
(40). TLRs are marginally expressed on IECs and are primarily
localized on the basolateral surface or in the endosomal vesi-
cles (41). Moreover, regulatory mechanisms such as the expres-
sion of TLR inhibitors like single immunoglobulin IL-1-related
receptor (SIGIRR), toll-interacting protein (TOLLIP), A20, and
IRAK3 are involved in the regulation of TLR signaling (42); these
inhibitory molecules prevent TLRs from mounting an immune
response even during continuous interaction (34, 43) and nurtur-
ing the anti-inflammatory phenotype of homing leukocytes (44).
SIGIRR-deficient mice demonstrate defective intestinal home-
ostasis, and these defects are associated with the microbiota
and hyper-expression of inflammatory mediators. Notably, these
defects also render the azoxymethane (AOM)-dextran sodium
sulfate (DSS)-treated SIGIRR−/− mice prone to colitis and colitis-
associated CRC. Interestingly, the rescue of SIGIRR expression
in the IECs of SIGIRR−/− mice restored the immune toler-
ance and abolished the risk of tumor development in these
mice (45).
Although elevated TLR activity disrupts the recognition of
intestinal microbes by TLR2 and TLR4, TLR signaling is neces-
sary for maintaining homeostasis and regulation of tissue repair
in IECs. MyD88-deficient mice, which hamper signaling through
IL-1 family members including TLRs, possess profound abnor-
malities in the mucosa with higher proliferation rates in the crypts
(46). Cumulatively, this leads to defects in repair of the intesti-
nal barrier following injury, and increased risk of colitis and CRC
(46, 47). Moreover, mice in which normal flora is disrupted by
antibiotics display a similar phenotype to mice lacking MyD88, as
well as decreased expression of factors [i.e., tumor necrosis factor
(TNF), CXC-chemokine ligand 1, IL-6, and heat shock proteins]
required for normal intestinal homeostasis (48).
RELATIONSHIP BETWEEN INFLAMMATION AND CRC
The direct link between intestinal inflammation and CRC progno-
sis is well-established and is also supported by numerous genetic,
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FIGURE 1 |TheTLR4 signaling pathway. TLR4 is activated by LPS, whereas
CD14 and MD2 act as accessory proteins for LPS/TLR4 binding. Upon ligand
binding, TLR4 dimerizes, and recruits downstream adaptor molecules such as
MyD88/MAL and TRIF/TRAM to mount an inflammatory response. The
activated MyD88/MAL then activates IRAK4, TRAF6, TAK1, and IKK
complexes, while TRIF/TRAM signals through RIP1 to TRAF6/TAK1 and IKK.
After this, both these pathways converge at NF-κB. The cytoplasmic NF-κB
complex is maintained in the inactive state by IκB, which is in turn degraded by
proteasomes, resulting in the translocation of NF-κB into the nucleus. Besides
activating NF-κB, TAK1 also phosphorylates MAPKs to further reinforce the
inflammatory response. The TRIF/TRAM pathway not only activates NF-κB but
also triggers IRF3 to mount an antiviral response. Cumulatively, all these
signaling pathways assist in eradicating infection as well as play an important
role in sustaining the normal physiological functions in IECs.
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pharmacological, and epidemiological studies conducted during
the last decade (49). Recent reports demonstrate the complex
interplay between distinct immune cells, and also show that pro-
inflammatory mediators influence almost all the steps of CRC
progression. However, the mechanisms by which inflammation
stimulates the development of cancer remain elusive and are
expected to vary from colitis-associated CRC to other forms of
CRC (25, 50). The relationship between inflammatory responses
caused by multiple factors such as the microbiota, IBD, and CRC
has been demonstrated by comparative experiments conducted in
wild type and Il10−/− mice. When treated with AOM, Il10-/- mice
were found to show an increased risk of colon tumor development,
spontaneous colitis, and CRC, while AOM-WT mice were devoid
of colitis and rarely progressed to adenomas. In addition,mice with
Bacteroides vulgatus or dual knockout mice (Il10- and MyD88-
deficient mice) treated with AOM showed reduced transcription
of Il12p40 and TNF-α and remained tumor-free (51).
TLR-induced inflammation is a well-established phenome-
non and is perpetuated by several cytokines, ILs, and TNF-α, all
of which are known to substantially regulate immune cells and
inflammatory responses against cancer (48, 52). Among these,
TNF-α is of particular importance and is now recognized as a
pro- as well as anti-tumorigenic protein (53). The activation of the
TLR4 signaling pathway induces TNF-α and NF-κB, leading to the
promotion of CRC (17,54–56); TNF-αknockout mice treated with
AOM/DSS show significantly less tumor formation, representing
the pro-tumorigenic role of TNF-α (57). Immunohistochemistry
analyses of mononuclear cells in the lamina propria and colons of
patients with advanced stage CRC demonstrate the expression of
TNF-α (57). TNF-α also promotes the activation of NF-κB, which
reinforces inflammation by inducing cyclooxygenase-2 (COX-2),
IL-6, IL-8, and TNF-α to favor tumorigenesis (55, 58, 59). How-
ever, inflammation alone is not sufficient for colon cancer and
the contribution of other risk factors is equally essential to the
pathogenesis of this complex disease.
CONTRIBUTION OF TLR4 TO CRC DEVELOPMENT
Although IECs are in close proximity to LPS, they do not mount
an immune response on the commensal bacteria under normal
circumstances. However, in the diseased state, disruption of the
coexistence between IECs, and bacteria leads to an inflammatory
response. This raises an important question: when and how much
inflammation should have to be raised in order to equilibrate the
bacterial threat (Figure 2). Numerous studies have been conducted
to address this dilemma (60–64). For instance, IFN-α and IFN-γ
are known to increase the LPS response in IECs, which is directly
linked to the expression of TLR4 and MD2 (63,65). Moreover, con-
tinuous LPS stimulation culminates in reduced TLR4 expression
and increased expression of inhibitory proteins (62). However, a
conflicting report demonstrated that long-term LPS exposure does
not alter TLR4 expression (66). Moreover, hypoxia and numerous
endotoxins are known to be prevalent in the inflamed intestinal
lining, possibly causing induced TLR4 expression (60). Hung et al.
observed an increase in the TLR4 expression from the mucosa of
CRC patients of different ages and sexes as well as from a variety
of CRC cell lines (HT29, SW480, and KM20) (67). In addition,
Maria and colleagues showed that TLR4 expression is required
FIGURE 2 | Homeostatic interaction between microbiota andTLRs.
TLRs play an important role in maintaining normal functions of IECs;
however, regulation of the activation and induction of TLRs through various
mechanisms is necessary for this role. TLRs in the intestine exist in close
proximity to and may be stimulated by commensal bacteria. Therefore, it is
extremely necessary to regulate their functions. Under normal conditions,
homeostasis between bacterial induction and TLR activation is maintained
to ensure a disease-free status. On the other hand, if TLRs are
inappropriately activated or if they mount an exaggerated immune response
to a low level stimulus, they may culminate in bacterial infection and
inflammatory disease/cancer, respectively.
for dysplasia and polyp formation. This finding is consistent with
results of experiments performed in TLR4 gene knockout mice
(56, 68). Collectively, these data present a clear association between
TLR4 and CRC development.
In CRC, elevated TLR4 expression is observed in all tumor
components such as the epithelial, endothelial, and stromal layers
(69). However, the level of this expression varies depending on the
type of cancer. Although all TLRs are expressed at the minimal
basal mRNA level, IECs can upregulate the TLR expression, based
on the inflammatory signals or other stimuli (70). An alternate
study demonstrated a low level of TLR4/MD2 expression in nor-
mal human colonic epithelial cells and the lamina propria, which
is consistent with the level of TLR4/MD2 expression detected in
various epithelial cell lines (71). These studies establish the fact
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that any alteration in the prevalent inflammatory conditions or
the population of luminal bacteria may influence the strength and
nature of TLR signaling, paving the way for initiation of inflam-
matory responses in IECs. Besides this negative role, studies in
TLR4- and TLR9-deficient mice have shown that TLR signaling in
IECs is essential for protecting the host from inflammation-related
damage and for homeostasis (46, 72).
TLR4 CROSSTALK IN CRC PROGRESSION
TLR4 is overexpressed in the liver metastasis of CRC (73). In
response to LPS binding, over-stimulation of the TLR4/MD2
complex enhances the phosphorylation of protein kinase B (also
known as AKT), which in turn activates the function of β1 integrin.
This complex interplay between multiple pathways promotes the
adhesiveness and metastatic behavior of CRC (74). The enhanced
AKT phosphorylation can be blocked by eritoran (a TLR4 antago-
nist), PI 103 [a phosphatidylinositide 3-kinases (PI3K) inhibitor],
or anti-β1 integrin antibodies that are known to ameliorate CRC
and its metastatic behavior (75–77), indicating that the PI3K/AKT
signaling pathway is induced by TLR4 in response to LPS binding
and plays a central role in the growth and progression of CRC. Fur-
thermore, LPS is known to induce the expression of the urokinase
plasminogen activator (uPA) system through TLR4 and NF-κB in
human colorectal cell lines. During tumor progression, vital extra-
cellular matrix (ECM) interactions occur, in which uPA and the
expression and activity of its receptor facilitate the growth and
metastasis of CRC (78). Conversely, inhibition of TLR4, NF-κB, or
the uPA system can attenuate CRC progression. Although NF-κB is
known to impair apoptosis in tumor cells (55, 79, 80), NF-κB acti-
vation through TNFR signaling also protects cells from apoptosis.
Studies performed in the Saos-2 cell line reveal that p53-induced
cell death is dependent on NF-κB, and the ablation of NF-κB
leads to the abrogation of p53-dependent cell death (81). Thus,
the TNF-α/NF-κB interaction plays a vital role in CRC and IBD-
related diseases and manipulation of this interaction may improve
the treatment of CRC.
TLR4 is overexpressed during inflammation-associated col-
orectal neoplasia in humans and mice. Similarly, mice lacking
TLR4 are largely protected from colon carcinogenesis (56). A
dissection of this mechanism reveals that TLR4 triggers elevated
production of prostaglandin E2, increases Cox-2 induction, and
influences epidermal growth factor receptor signaling (EGFR)
in chronic colitis. TLR4 can thus manipulate numerous path-
ways and cause further deterioration of the neoplastic situation.
A recent comparative immunohistochemistry analysis between
normal mucosa and adenomas showed that TLR4 and MD2
are overexpressed in 20 and 23% of the adenomas, respectively
(82), further substantiating the involvement of the TLR4 path-
way in CRC. Furthermore, mutations in the APC gene cause
pre-disposition to CRC. A correlation between the TLR/MyD88
signaling pathway and APC mutations was recently proposed (82,
83) since MyD88 signaling was found to facilitate the growth of
intestinal polyps while the ablation of MyD88 restricted polyp
growth in Apcmin/+/Myd88−/− mice, but not in Apcmin/+ mice
(83, 84). In addition, MyD88 induces ERK to block the degra-
dation of the oncoprotein c-Myc, and such cells with continued
activation of c-Myc are prone to neoplastic transformation (85).
Similarly, c-Myc is also important for APC-mediated tumorige-
nesis (86), since knocking out c-Myc in IECs of Apcmin/+ mice
impedes tumor growth (84). Furthermore, reduced expression
of c-Myc has been reported in Apcmin/+/Myd88-/- of both nor-
mal and tumor mice (84, 87). Treatment of Apcmin/+ mice with
PD03259012, an inhibitor of MEK1/2, which is the kinase directly
upstream of ERK, also inhibits tumor growth. These data indi-
cate that a complex interplay of protein signaling brings about
tumor proliferation in the IECs of various transgenic mouse mod-
els. Moreover, heritable changes in the APC gene frequently lead
to familial adenomatous polyposis (FAP). FAP is the most domi-
nant inherited syndrome of CRC (88, 89) and Apcmin/+mice show
increased propensity for the development of adenomatous polyps
after the loss of the wild type APC allele (88). Up to 80% of spo-
radic CRCs are known to be initiated by DNA damage of the genes
involved in the APC signaling pathway (87).
CORRELATION BETWEEN CRC DEVELOPMENT AND
INHERITED GENETIC VARIATIONS OF TLR4
The human TLR4 gene is located on the long (q) arm of
chromosome 9 at position 33.1, and contain four exons. The
dominant expression of TLR4 has been observed in lympho-
cytes, monocytes, leukocytes, and splenocytes (90). Besides CRC,
many human pathologies and carcinomas are associated with the
polymorphisms of TLR4 (91–93). The TLR4 gene contains two
single-nucleotide polymorphisms (SNPs), namely, Asp299Gly and
Thr399Ile that are significantly important in tumor development
(94, 95). Both these SNPs are located in the coding sequence for the
TLR4 ectodomain and mediate an amino acid substitution. These
Asp299Gly and Thr399Ile SNPs in TLR4 are known to attenu-
ate cytokine expression, leading to an increased propensity for the
development of gastric cancer and CRC (94, 96–99). The detection
of these two SNPs was carried out using allele-specific polymerase
chain reaction and the primer extension method (SNaPshot) for
gastric cancer and CRC, respectively. For gastric cancer, only
Thr399Ile showed a significant correlation, while both the SNPs
were significantly correlated to CRC (94, 100, 101). In addition,
the association of the TLR3 (rs3775291) polymorphism and IL-10
promoter variation (rs1800872) to CRC pathogenesis was evalu-
ated in a large cohort of German CRC patients. This study found
that the IL-10 promoter variant is significantly associated with
an increased risk of lymph node metastasis (for carriers of the TT
genotype). Interestingly, a TLR3 gene polymorphism was found to
correlate with patient survival, and the TT genotype was responsi-
ble for increased mortality. This TLR3 variation was limited only
to stage II patients who were devoid of adjuvant therapy (102, 103).
The LPS-sensing complex is comprises TLR4, MD2, LPS bind-
ing protein, and CD14. A positive link between CD14–260 poly-
morphisms and the occurrence of CRC in the Chinese Han
population was demonstrated (104, 105), in which the CD14 poly-
morphism C/C, but not C/T, was significantly correlated to CRC;
no correlation between TLR4 Asp299Gly and CRC was found.
However, it is possible that the polymorphism in TLR4 was associ-
ated with the population under study (106). A multi-racial study
(22 Malays, 20 Chinese, and 18 Indians) conducted in Malaysia
showed that there is no correlation between TLR4 polymorphisms
(Asp299Gly; Thr399Ile) and the risk of CRC (107). However, a
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study on Russian population revealed that IL1B_1473G/C and
TLR4_896A/G SNPs are involved in rectal cancer development
(108). A conflicting report validated the potential link between
TLR4 polymorphisms (Asp299Gly and Thr399Ile) and the diges-
tive tract cancer and CRC (101). This study retrieved and ana-
lyzed extensive data from various databases and concluded that
Asp299Gly is significantly correlated with an increased risk of
gastric cancer, while there was no correlation between this poly-
morphism and digestive tract cancer and CRC. Moreover, it was
also observed that the T allele of Thr399Ile does not influence
digestive tract, gastric, or CRC. It is evident that additional studies
are necessary to support these findings.
EPIGENETIC REGULATION OF TLR4 IN CRC
Intestinal epithelial cells are stimulated by the commensal bacteria
in the intestinal lumen with the help of TLRs for the main-
tenance of homeostasis. This stimulation from the commensal
bacteria is finite, should not trigger an excessive inflammatory
response, and is known to influence epigenetic modification in
the host cells (109). These epigenetic modifications involve DNA
methylation and histone deacetylation that suppress and promote
the transcription process, respectively, and in turn regulate gene
expression (110).
The TLR4 gene is methylated in the 5′ region; also, the degree
of methylation in epithelial cells is higher than that in the splenic
cells, caused by the interaction of the commensal bacterial with
IECs. Takahashi and colleagues showed that commensal bacteria
modulate the epigenetic regulation in IECs by DNA methylation of
TLR4 (111). In their study, the authors compared the methylation
levels in the IECs from the small and large intestine obtained from
conventional (CV) mice with commensal bacteria and germ-free
(GF) mice without commensal bacteria. The methylation level of
CpG motifs in the 5′ region of TLR4 from the large intestine was
lower in the GF mice compared with CV mice, while in the small
intestine, the methylation levels remained unchanged between the
GF and CV mice. The frequency of methylation is also found to
depend on the MyD88 adaptor molecule. Results from in vivo
experiments show that the frequency of CpG methylation is less in
the GF mice (MyD88 knockout mice) compared to CV mice (111).
Environmental factors also play a crucial role in regulating epi-
genetic modifications. In the presence of factors such as myriad
food habits and increasing pollution, intestinal commensal bacte-
ria produce short-chain fatty acids known as butyrates that inhibit
histone deacetylation (112, 113). Besides TLR4, MD2 can also be
downregulated to attenuate the LPS response. IECs are known to
poorly express MD2, which directly correlates to DNA hyperme-
thylation (114). In IBD, IECs exhibit elevated expression of MD2
and TLR4 mRNA, while in normal cells; TLR4/MD2 transcrip-
tion is reduced due to DNA methylation. The deacetylation and
blocking of methylation enables cells to express higher amounts
of TLR4 and MD2 mRNA. This study demonstrates how epi-
genetic regulation of TLR4 and MD2 prevents dysregulation of
inflammation in IECs and thus provides a novel approach to
target CRC.
THERAPEUTIC TARGETING OF TLR4
Synthetic TLR4 ligands are potential targets for therapeutic appli-
cations for cancer, allergies, and viral infections (115). By virtue
of their cell surface location, quick induction, and the ability to
mount a wide array of inflammatory responses, TLRs are one of
the most promising targets for therapeutics (91). The clinical trials
of various TLR4 ligands are enlisted in Table 1.
TLR4 agonists have immune regulatory applications as adju-
vants in vaccines and in the treatment of chronic viral infection
and cancer therapy. LPS was the first microbial product iden-
tified as a potential TLR4 agonist and implemented for ther-
apeutic applications (116). LPS is very toxic since it induces
excessive inflammatory cytokines. However, low-dose LPS com-
bined with non-steroidal anti-inflammatory drug ibuprofene was
proved to be safe, with higher levels of TNF-α and IL-1 in
all patients (117, 118). Marginal to encouraging results were
observed when ibuprofene combined with Salmonella abortus
Table 1 |TLR4 agonists in clinical trials.
Compounds Phase Note Indications Current status ClinicalTrail.gov
LPS I–II Combined with KLH-pulsed DCs vaccine Neuroblastoma and Ewing’s
sarcoma
Active, not recruiting NCT00923351
I–II Combined with IL-4, KLH, and WT1
peptide-pulsed DC based vaccine
Hematologic malignancies Completed NCT00923910
I Combined with multipeptide vaccine Melanoma Active, not recruiting NCT01585350
OM-174 I Injections of OM-174 Solid tumors Completed NCT01800812
Stimuvax II Combined with chemoradiation therapy Rectal cancer Active, not recruiting NCT01507103
II Androgen deprivation and radiation therapy Prostate cancer Recruiting NCT01496131
II L-BLP25 vaccination Colorectal carcinoma Recruiting NCT01462513
Picibanil IV Intracystic injection Cystic malformation Recruiting NCT01699347
I–II Combined with pre-operative intra tumoral
DCs
Pancreatic cancer Unknown NCT00795977
I Combined with cyclophosphamide,
docetaxel (chemo-immunotherapy)
Head and neck cancer Unknown NCT01149902
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equi LPS for non-small cell lung carcinoma (NSCLC) and CRC
patients, respectively (119). Currently, a few clinical trials are
being conducted for oncological indications involving cell-based
vaccination to treat Ewing sarcoma, neuroblastoma, and rhab-
domyosarcoma patients (NCT00923351). Besides, peptide-pulsed
dendritic cells (DCs) were combined with LPS to treat hema-
tological malignancies (NCT00923910), and to treat melanoma
patients (NCT01585350), LPS along with oil-based adjuvant and
a peptide vaccine are being investigated (119). A less toxic TLR4
agonist, monophosphoryl lipid A (MPLA), is an immunity modu-
lating agent that activates MyD88-independent pathway in TLR4
signaling, triggers the induction of IFN-γ, and regulation of
CD80/86, which forms the crucial aspect of adjuvancy (27, 120).
MPLA adjuvant plays a dual role in defending the host from
pathogens by stimulating the innate immune system, and induces
the long-term adaptive immune system (115, 121, 122). Food
and Drug Administration has approved MPLA to use as a vac-
cine against HPV associated cervical cancer (Cervarix). It also
enhances the inflammatory behavior of immune cells, which
may be useful in a variety of cancers to overcome the cancer-
induced immune suppression. However, this may not be help-
ful in case of CRC, where TLR should emphasize the tolerance
of immune system, not the over-activation. Furthermore, it is
established that TLRs can act as double-edge sword that may
be exploited in pathologies-dependent circumstances to avoid
the undesirable consequences (123). OM-174 is a triacyl lipid
A analog that activates TLR4 and culminates in tumor growth
regression by increasing the IFN-γ production (124, 125) This is
well-tolerated at biological concentrations with strong antitumor
effects (NCT01800812) (126). A new anti-cancer vaccine, BLP25
liposome vaccine (Stimuvax), can identify and destroy the cancer
antigen MUC1, thereby inducing an immune response against
cancer cells (127, 128). However, this could not significantly
improve the NSCLC (128). Now, stimuvax is being investigated for
the treatment of rectal and prostate cancers (NCT01507103 and
NCT01496131). Group A Streptococcus pyogenes [in lyophilized
form OK-432 (Picibanil)] is shown to stimulate TLR4, which is
used to treat gastric, cervical, and oral cancers (119). This com-
pound is currently being examined to treat pancreatic cancer
patients in pre-operative settings using intra tumoral injection of
DCs (NCT00795977), combined with chemotherapy (cyclophos-
phamide+ docetaxel) for head and neck squamous cell carcinoma
(HNSCC) patients (NCT01149902), and via intracystic injection
at cystic malformation (NCT01699347). Currently, most of the
TLR4 antagonists are being evaluated against cancer-unrelated
symptoms.
CONCLUSION AND FUTURE PERSPECTIVES
In this review, we highlight the correlation between CRC and
TLRs, in particular, TLR4. We also propose that a beneficial
link exists between commensal bacteria and TLRs in order to
maintain intestinal homeostasis. In IECs, TLRs are involved in
epithelial cell proliferation, IgA production, regulating the per-
meability of the intestinal barrier, antimicrobial peptide expres-
sion, and defense against invading pathogens. Over-stimulation
of TLRs in response to minor signals (due to dysregulation)
may result in colitis and CRC. Several studies suggested the
relationship of TLR4 signaling with CRC, therefore therapeu-
tic benefit can be achieved by targeting TLR4. However, the
development of CRC is highly complex. Experimental studies
supported that the gut microbiota contributed to CRC. The
studies involving human subjects and considering their micro-
biota composition revealed the vivid differences in microbial
density and population. Therefore, modulating the microbial
population, usage of probiotics to favor the growth of cer-
tain bacteria, and delineating the interaction of microbiota with
the epithelial cells can potentially be used to limit the CRC
development.
Furthermore, inflammation is central to the development of
cancer, and there are few clinical trials being conducted for anti-
inflammatory drugs, but by combining molecular approaches with
CV therapies, i.e., chemo- or radiotherapy, anti-inflammatory
drugs would increase the efficacy to treat CRC. Additionally, tar-
geting the downstream molecules in TLR4 pathway involved in
CRC is also expected to have a tremendous impact on CRC thera-
peutics. Moreover, differential expression of TLRs leads to tumor
development, in which the contribution of TLR4 is considerably
higher than in the other TLRs. We hope that extensive studies
involving the TLR4 pathway will eventually provide therapeu-
tic targets to treat CRC. Recently developed techniques may also
prove helpful in the analyses of differential expression levels of
TLRs, their mutations, and epigenetic modifications. These analy-
ses would further aid in the design and development of novel
therapeutic approaches for CRC treatment.
ACKNOWLEDGMENTS
This work was supported by the Mid-Career Researcher Pro-
gram through the National Research Foundation of Korea,
funded by the Ministry of Education, Science, and Technology
(2012R1A2A2A02016803), and partly supported by a grant from
the Priority Research Centers Program (NRF 2012-0006687).
REFERENCES
1. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol (2004)
4(7):499–511. doi:10.1038/nri1391
2. Oldenburg M,Kruger A,Ferstl R,Kaufmann A,Nees G,Sigmund A,et al. TLR13
recognizes bacterial 23S rRNA devoid of erythromycin resistance-forming
modification. Science (2012) 337(6098):1111–5. doi:10.1126/science.1220363
3. Kawai T,Akira S. The role of pattern-recognition receptors in innate immunity:
update on toll-like receptors. Nat Immunol (2010) 11(5):373–84. doi:10.1038/
ni.1863
4. Takeuchi O, Kaufmann A, Grote K, Kawai T, Hoshino K, Morr M, et al. Cut-
ting edge: preferentially the R-stereoisomer of the mycoplasmal lipopeptide
macrophage-activating lipopeptide-2 activates immune cells through a toll-
like receptor 2- and MyD88-dependent signaling pathway. J Immunol (2000)
164(2):554–7. doi:10.4049/jimmunol.164.2.554
5. Takeuchi O, Sato S, Horiuchi T, Hoshino K, Takeda K, Dong Z, et al. Cutting
edge: role of toll-like receptor 1 in mediating immune response to microbial
lipoproteins. J Immunol (2002) 169(1):10–4. doi:10.4049/jimmunol.169.1.10
6. Takeuchi O, Kawai T, Muhlradt PF, Morr M, Radolf JD, Zychlinsky A, et al.
Discrimination of bacterial lipoproteins by toll-like receptor 6. Int Immunol
(2001) 13(7):933–40. doi:10.1093/intimm/13.7.933
7. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA. Recognition of double-
stranded RNA and activation of NF-kappaB by toll-like receptor 3. Nature
(2001) 413(6857):732–8. doi:10.1038/35099560
8. Poltorak A, He X, Smirnova I, Liu MY, Van Huffel C, Du X, et al. Defective LPS
signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science
(1998) 282(5396):2085–8. doi:10.1126/science.282.5396.2085
www.frontiersin.org July 2014 | Volume 5 | Article 334 | 7
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yesudhas et al. Roles of TLR4 in CRC development
9. Hayashi F, Smith KD, Ozinsky A, Hawn TR, Yi EC, Goodlett DR, et al. The
innate immune response to bacterial flagellin is mediated by toll-like receptor
5. Nature (2001) 410(6832):1099–103. doi:10.1038/35074106
10. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis E, Sousa C. Innate antiviral
responses by means of TLR7-mediated recognition of single-stranded RNA.
Science (2004) 303(5663):1529–31. doi:10.1126/science.1093616
11. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, et al.
Species-specific recognition of single-stranded RNA via toll-like receptor 7 and
8. Science (2004) 303(5663):1526–9. doi:10.1126/science.1093620
12. Hemmi H, Takeuchi O, Kawai T, Kaisho T, Sato S, Sanjo H, et al. A toll-
like receptor recognizes bacterial DNA. Nature (2000) 408(6813):740–5.
doi:10.1038/35047123
13. Krug A, French AR, Barchet W, Fischer JA, Dzionek A, Pingel JT, et al. TLR9-
dependent recognition of MCMV by IPC and DC generates coordinated
cytokine responses that activate antiviral NK cell function. Immunity (2004)
21(1):107–19. doi:10.1016/j.immuni.2004.06.007
14. Gosu V, Basith S, Kwon OP, Choi S. Therapeutic applications of nucleic
acids and their analogues in toll-like receptor signaling. Molecules (2012)
17(11):13503–29. doi:10.3390/molecules171113503
15. Lavelle EC, Murphy C, O’Neill LA, Creagh EM. The role of TLRs, NLRs, and
RLRs in mucosal innate immunity and homeostasis. Mucosal Immunol (2010)
3(1):17–28. doi:10.1038/mi.2009.124
16. Rakoff-Nahoum S, Medzhitov R. Role of toll-like receptors in tissue repair
and tumorigenesis. Biochemistry (Mosc) (2008) 73(5):555–61. doi:10.1134/
S0006297908050088
17. So EY, Ouchi T. The application of toll like receptors for cancer therapy. Int
J Biol Sci (2010) 6(7):675–81. doi:10.7150/ijbs.6.675
18. Keogh B, Parker AE. Toll-like receptors as targets for immune disorders. Trends
Pharmacol Sci (2011) 32(7):435–42. doi:10.1016/j.tips.2011.03.008
19. Shi Z, Cai Z, Sanchez A, Zhang T, Wen S, Wang J, et al. A novel toll-like receptor
that recognizes vesicular stomatitis virus. J Biol Chem (2011) 286(6):4517–24.
doi:10.1074/jbc.M110.159590
20. Karin M. Nuclear factor-kappaB in cancer development and progression.
Nature (2006) 441(7092):431–6. doi:10.1038/nature04870
21. Karin M, Greten FR. NF-kappaB: linking inflammation and immunity to can-
cer development and progression. Nat Rev Immunol (2005) 5(10):749–59.
doi:10.1038/nri1703
22. Frolova L, Drastich P, Rossmann P, Klimesova K, Tlaskalova-Hogenova H.
Expression of toll-like receptor 2 (TLR2), TLR4, and CD14 in biopsy samples
of patients with inflammatory bowel diseases: upregulated expression of TLR2
in terminal ileum of patients with ulcerative colitis. J Histochem Cytochem
(2008) 56(3):267–74. doi:10.1369/jhc.7A7303.2007
23. Smith RA, Brooks D, Cokkinides V, Saslow D, Brawley OW. Cancer screen-
ing in the United States, 2013. CA Cancer J Clin (2013) 63(2):87–105.
doi:10.3322/caac.21174
24. Tenesa A, Dunlop MG. New insights into the aetiology of colorectal cancer
from genome-wide association studies. Nat Rev Genet (2009) 10(6):353–8.
doi:10.1038/nrg2574
25. Terzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer.
Gastroenterology (2010) 138(6): 2101–14.e5. doi:10.1053/j.gastro.2010.01.058
26. Adelstein BA, Macaskill P, Chan SF, Katelaris PH, Irwig L. Most bowel cancer
symptoms do not indicate colorectal cancer and polyps: a systematic review.
BMC Gastroenterol (2011) 11:65. doi:10.1186/1471-230X-11-65
27. Evans JT, Cluff CW, Johnson DA, Lacy MJ, Persing DH, Baldridge JR. Enhance-
ment of antigen-specific immunity via the TLR4 ligands MPL adjuvant and
Ribi.529. Expert Rev Vaccines (2003) 2(2):219–29. doi:10.1586/14760584.2.2.
219
28. Blasius AL, Beutler B. Intracellular toll-like receptors. Immunity (2010)
32(3):305–15. doi:10.1016/j.immuni.2010.03.012
29. Gosu V, Basith S, Durai P, Choi S. Molecular evolution and structural features
of IRAK family members. PLoS One (2012) 7(11):e49771. doi:10.1371/journal.
pone.0049771
30. Chen ZJ. Ubiquitin signalling in the NF-κB pathway. Nat Cell Biol (2005)
7(8):758–65. doi:10.1038/ncb0805-758
31. Sato S,Sanjo H,Takeda K,Ninomiya-Tsuji J,Yamamoto M,Kawai T,et al. Essen-
tial function for the kinase TAK1 in innate and adaptive immune responses.
Nat Immunol (2005) 6(11):1087–95. doi:10.1038/ni1255
32. Takeda K, Akira S. TLR signaling pathways. Semin Immunol (2004) 16(1):3–9.
doi:10.1016/j.smim.2003.10.003
33. Moossavi S, Rezaei N. Toll-like receptor signalling and their therapeutic
targeting in colorectal cancer. Int Immunopharmacol (2013) 16(2):199–209.
doi:10.1016/j.intimp.2013.03.017
34. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how
bacterial recognition shapes intestinal function. Nat Rev Immunol (2010)
10(2):131–44. doi:10.1038/nri2707
35. Khan MA, Ma C, Knodler LA, Valdez Y, Rosenberger CM, Deng W, et al. Toll-
like receptor 4 contributes to colitis development but not to host defense during
Citrobacter rodentium infection in mice. Infect Immun (2006) 74(5):2522–36.
doi:10.1128/IAI.74.5.2522-2536.2006
36. Lebeis SL, Bommarius B, Parkos CA, Sherman MA, Kalman D. TLR signal-
ing mediated by MyD88 is required for a protective innate immune response
by neutrophils to Citrobacter rodentium. J Immunol (2013) 179:566–77.
doi:10.4049/jimmunol.179.1.566.
37. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expres-
sion of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease.
Infect Immun (2000) 68(12):7010–7. doi:10.1128/IAI.68.12.7010-7017.2000
38. Gewirtz AT, Navas TA, Lyons S, Godowski PJ, Madara JL. Cutting edge:
bacterial flagellin activates basolaterally expressed TLR5 to induce epithe-
lial proinflammatory gene expression. J Immunol (2001) 167(4):1882–5.
doi:10.4049/jimmunol.167.4.1882
39. Grimm M, Kim M, Rosenwald A, Heemann U, Germer C-T, Waaga-Gasser
AM, et al. Toll-like receptor (TLR) 7 and TLR8 expression on CD133 + cells in
colorectal cancer points to a specific role for inflammation-induced TLRs in
tumourigenesis and tumour progression. Eur J Cancer (2010) 46(15):2849–57.
doi:10.1016/j.ejca.2010.07.017
40. Medzhitov R. Origin and physiological roles of inflammation. Nature (2008)
454(7203):428–35. doi:10.1038/nature07201
41. Liew FY, Xu D, Brint EK, O’Neill LA. Negative regulation of toll-like receptor-
mediated immune responses. Nat Rev Immunol (2005) 5(6):446–58. doi:10.
1038/nri1630
42. Anwar MA, Basith S, Choi S. Negative regulatory approaches to the attenuation
of toll-like receptor signaling. Exp Mol Med (2013) 45:e11. doi:10.1038/emm.
2013.28
43. Lebeer S, Vanderleyden J, De Keersmaecker SC. Host interactions of probiotic
bacterial surface molecules: comparison with commensals and pathogens. Nat
Rev Microbiol (2010) 8(3):171–84. doi:10.1038/nrmicro2297
44. Hooper LV, Macpherson AJ. Immune adaptations that maintain homeosta-
sis with the intestinal microbiota. Nat Rev Immunol (2010) 10(3):159–69.
doi:10.1038/nri2710
45. Xiao H, Gulen MF, Qin J, Yao J, Bulek K, Kish D, et al. The toll-interleukin-
1 receptor member SIGIRR regulates colonic epithelial homeostasis, inflam-
mation, and tumorigenesis. Immunity (2007) 26(4):461–75. doi:10.1016/j.
immuni.2007.02.012
46. Rakoff NS, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recogni-
tion of commensal microflora by toll-like receptors is required for intestinal
homeostasis. Cell (2004) 118(2):229–41. doi:10.1016/j.cell.2004.07.002
47. Salcedo R, Worschech A, Cardone M, Jones Y, Gyulai Z, Dai RM, et al. MyD88-
mediated signaling prevents development of adenocarcinomas of the colon:
role of interleukin 18. J Exp Med (2010) 207(8):1625–36. doi:10.1084/jem.
20100199
48. Clevers H. At the crossroads of inflammation and cancer. Cell (2004)
118(6):671–4. doi:10.1016/j.cell.2004.09.005
49. Elinav E,Nowarski R,Thaiss CA,Hu B, Jin C,Flavell RA. Inflammation-induced
cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev
Cancer (2013) 13(11):759–71. doi:10.1038/nrc3611
50. Ullman TA, Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology
(2011) 140(6):1807–16. doi:10.1053/j.gastro.2011.01.057
51. Uronis JM, Mühlbauer M, Herfarth HH, Rubinas TC, Jones GS, Jobin C. Mod-
ulation of the intestinal microbiota alters colitis-associated colorectal cancer
susceptibility. PLoS One (2009) 4(6):e6026. doi:10.1371/journal.pone.0006026
52. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. Demon-
stration of inflammation-induced cancer and cancer immunoediting dur-
ing primary tumorigenesis. Proc Natl Acad Sci U S A (2008) 105(2):652–6.
doi:10.1073/pnas.0708594105
Frontiers in Immunology | Tumor Immunity July 2014 | Volume 5 | Article 334 | 8
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yesudhas et al. Roles of TLR4 in CRC development
53. Balkwill F. Tumour necrosis factor and cancer. Nat Rev Cancer (2009)
9(5):361–71. doi:10.1038/nrc2628
54. Govind S. Control of development and immunity by rel transcription factors
in Drosophila. Oncogene (1999) 18(49):6875–87. doi:10.1038/sj.onc.1203223
55. Perkins ND. NF-kappaB: tumor promoter or suppressor? Trends Cell Biol
(2004) 14(2):64–9. doi:10.1016/j.tcb.2003.12.004
56. Fukata M, Chen A, Vamadevan AS, Cohen J, Breglio K, Krishnareddy S, et al.
Toll-like receptor-4 promotes the development of colitis-associated colorec-
tal tumors. Gastroenterology (2007) 133(6):1869–81. doi:10.1053/j.gastro.2007.
09.008
57. Popivanova BK, Kitamura K,Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Blocking
TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic
colitis. J Clin Invest (2008) 118(2):560–70. doi:10.1172/JCI32453
58. Oshima H, Oshima M. The inflammatory network in the gastrointestinal
tumor microenvironment: lessons from mouse models. J Gastroenterol (2012)
47(2):97–106. doi:10.1007/s00535-011-0523-6
59. Ogino S, Kirkner GJ, Nosho K, Irahara N, Kure S, Shima K, et al.
Cyclooxygenase-2 expression is an independent predictor of poor prognosis in
colon cancer. Clin Cancer Res (2008) 14(24):8221–7. doi:10.1158/1078-0432.
CCR-08-1841
60. Leaphart CL, Cavallo J, Gribar SC, Cetin S, Li J, Branca MF, et al. A critical
role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating
intestinal injury and repair. J Immunol (2007) 179(7):4808–20. doi:10.4049/
jimmunol.179.7.4808
61. Jilling T, Simon D, Lu J, Meng FJ, Li D, Schy R, et al. The roles of bacteria and
TLR4 in rat and murine models of necrotizing enterocolitis. J Immunol (2006)
177(5):3273–82. doi:10.4049/jimmunol.177.5.3273
62. Otte JM, Cario E, Podolsky DK. Mechanisms of cross hyporesponsiveness to
toll-like receptor bacterial ligands in intestinal epithelial cells. Gastroenterology
(2004) 126(4):1054–70. doi:10.1053/j.gastro.2004.01.007
63. Abreu MT, Vora P, Faure E, Thomas LS, Arnold ET, Arditi M. Decreased
expression of toll-like receptor-4 and MD-2 correlates with intestinal epithe-
lial cell protection against dysregulated proinflammatory gene expression in
response to bacterial lipopolysaccharide. J Immunol (2001) 167(3):1609–16.
doi:10.4049/jimmunol.167.3.1609
64. Suzuki M, Hisamatsu T, Podolsky DK. Gamma interferon augments the intra-
cellular pathway for lipopolysaccharide (LPS) recognition in human intestinal
epithelial cells through coordinated up-regulation of LPS uptake and expres-
sion of the intracellular toll-like receptor 4-MD-2 complex. Infect Immun
(2003) 71(6):3503–11. doi:10.1128/IAI.71.6.3503-3511.2003
65. Abreu MT, Arnold ET, Thomas LS, Gonsky R, Zhou Y, Hu B, et al. TLR4
and MD-2 expression is regulated by immune-mediated signals in human
intestinal epithelial cells. J Biol Chem (2002) 277(23):20431–7. doi:10.1074/
jbc.M110333200
66. Hornef MW, Frisan T, Vandewalle A, Normark S, Richter-Dahlfors A. Toll-
like receptor 4 resides in the Golgi apparatus and colocalizes with inter-
nalized lipopolysaccharide in intestinal epithelial cells. J Exp Med (2002)
195(5):559–70. doi:10.1084/jem.20011788
67. Doan HQ, Bowen KA, Jackson LA, Evers BM. Toll-like receptor 4 activation
increases Akt phosphorylation in colon cancer cells. Anticancer Res (2009)
29(7):2473–8.
68. Fukata M, Chen A, Klepper A, Krishnareddy S, Vamadevan AS, Thomas LS,
et al. Cox-2 is regulated by toll-like receptor-4 (TLR4) signaling: role in prolif-
eration and apoptosis in the intestine. Gastroenterology (2006) 131(3):862–77.
doi:10.1053/j.gastro.2006.06.017
69. Cammarota R, Bertolini V, Pennesi G, Bucci EO, Gottardi O, Garlanda C,
et al. The tumor microenvironment of colorectal cancer: stromal TLR-4
expression as a potential prognostic marker. J Transl Med (2010) 8(1):112.
doi:10.1186/1479-5876-8-112
70. Fukata M, Abreu MT. TLR4 signalling in the intestine in health and disease.
Biochem Soc Trans (2007) 35(Pt 6):1473–8. doi:10.1042/BST0351473
71. Abreu MT, Thomas LS,Arnold ET, Lukasek K, Michelsen KS,Arditi M. TLR sig-
naling at the intestinal epithelial interface. J Endotoxin Res (2003) 9(5):322–30.
doi:10.1179/096805103225002593
72. Katakura K, Lee J, Rachmilewitz D, Li G, Eckmann L, Raz E. Toll-like receptor
9 – induced type I IFN protects mice from experimental colitis. J Clin Invest
(2005) 115(3):695–702. doi:10.1172/JCI200522996C1
73. Laird MH, Rhee SH, Perkins DJ, Medvedev AE, Piao W, Fenton MJ, et al.
TLR4/MyD88/PI3K interactions regulate TLR4 signaling. J Leukoc Biol (2009)
85(6):966–77. doi:10.1189/jlb.1208763
74. Sheng H, Shao J, Townsend CM Jr, Evers BM. Phosphatidylinositol 3-
kinase mediates proliferative signals in intestinal epithelial cells. Gut (2003)
52(10):1472–8. doi:10.1136/gut.52.10.1472
75. Somanath PR, Kandel ES, Hay N, Byzova TV. Akt1 signaling regulates integrin
activation, matrix recognition, and fibronectin assembly. J Biol Chem (2007)
282(31):22964–76. doi:10.1074/jbc.M700241200
76. Hsu RY, Chan CH, Spicer JD, Rousseau MC, Giannias B, Rousseau S, et al.
LPS-induced TLR4 signaling in human colorectal cancer cells increases beta1
integrin-mediated cell adhesion and liver metastasis. Cancer Res (2011)
71(5):1989–98. doi:10.1158/0008-5472.CAN-10-2833
77. Earl TM, Nicoud IB, Pierce JM, Wright JP, Majoras NE, Rubin JE, et al. Silenc-
ing of TLR4 decreases liver tumor burden in a murine model of colorec-
tal metastasis and hepatic steatosis. Ann Surg Oncol (2009) 16(4):1043–50.
doi:10.1245/s10434-009-0325-8
78. Killeen S, Wang J, Andrews E, Redmond H. Bacterial endotoxin enhances
colorectal cancer cell adhesion and invasion through TLR-4 and NF-κB-
dependent activation of the urokinase plasminogen activator system. Br J Can-
cer (2009) 100(10):1589–602. doi:10.1038/sj.bjc.6604942
79. Baldwin AS. Control of oncogenesis and cancer therapy resistance by the tran-
scription factor NF-kappaB. J Clin Invest (2001) 107(3):241–6. doi:10.1172/
JCI11991
80. Hatta Y, Koeffler HP. Role of tumor suppressor genes in the development
of adult T cell leukemia/lymphoma (ATLL). Leukemia (2002) 16(6):1069–85.
doi:10.1038/sj.leu.2402458
81. Ryan KM, Ernst MK, Rice NR, Vousden KH. Role of NF-kappaB in p53-
mediated programmed cell death. Nature (2000) 404(6780):892–7. doi:10.
1038/35009130
82. Wang EL, Qian ZR, Nakasono M, Tanahashi T, Yoshimoto K, Bando Y, et al.
High expression of toll-like receptor 4/myeloid differentiation factor 88 sig-
nals correlates with poor prognosis in colorectal cancer. Br J Cancer (2010)
102(5):908–15. doi:10.1038/sj.bjc.6605558
83. Rakoff NS, Medzhitov R. Regulation of spontaneous intestinal tumorigen-
esis through the adaptor protein MyD88. Science (2007) 317(5834):124–7.
doi:10.1126/science.1140488
84. Lee SH, Hu LL, Gonzalez-Navajas J, Seo GS, Shen C, Brick J, et al. ERK acti-
vation drives intestinal tumorigenesis in Apc(min/+) mice. Nat Med (2010)
16(6):665–70. doi:10.1038/nm.2143
85. Gustafson WC,Weiss WA. Myc proteins as therapeutic targets. Oncogene (2010)
29(9):1249–59. doi:10.1038/onc.2009.512
86. Wilkins JA, Sansom OJ. C-Myc is a critical mediator of the phenotypes of Apc
loss in the intestine. Cancer Res (2008) 68(13):4963–6. doi:10.1158/0008-5472.
CAN-07-5558
87. Fukata M, Abreu MT. Microflora in colorectal cancer: a friend to fear. Nat Med
(2010) 16(6):639–41. doi:10.1038/nm0610-639
88. Groden J, Thliveris A, Samowitz W, Carlson M, Gelbert L, Albertsen H, et al.
Identification and characterization of the familial adenomatous polyposis coli
gene. Cell (1991) 66(3):589–600. doi:10.1016/0092-8674(81)90021-0
89. Goss KH, Groden J. Biology of the adenomatous polyposis coli tumor suppres-
sor. J Clin Oncol (2000) 18(9):1967–79.
90. Opal SM, Esmon CT. Bench-to-bedside review: functional relationships
between coagulation and the innate immune response and their respec-
tive roles in the pathogenesis of sepsis. Crit Care (2002) 7(1):23. doi:10.1186/
cc1854
91. Hennessy EJ, Parker AE, O’Neill LA. Targeting toll-like receptors: emerging
therapeutics? Nat Rev Drug Discov (2010) 9(4):293–307. doi:10.1038/nrd3203
92. Slattery ML, Herrick JS, Bondurant KL, Wolff RK. Toll-like receptor genes and
their association with colon and rectal cancer development and prognosis. Int
J Cancer (2012) 130(12):2974–80. doi:10.1002/ijc.26314
93. Pimentel-Nunes P, Teixeira AL, Pereira C, Gomes M, Brandao C, Rodrigues
C, et al. Functional polymorphisms of toll-like receptors 2 and 4 alter the
risk for colorectal carcinoma in Europeans. Dig Liver Dis (2013) 45(1):63–9.
doi:10.1016/j.dld.2012.08.006
94. Omrane I, Baroudi O, Kourda N, Bignon YJ, Uhrhammer N, Desrichard A, et al.
Positive link between variant toll-like receptor 4 (Asp299Gly and Thr399Ile)
www.frontiersin.org July 2014 | Volume 5 | Article 334 | 9
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Yesudhas et al. Roles of TLR4 in CRC development
and colorectal cancer patients with advanced stage and lymph node metastasis.
Tumour Biol (2013) 35(1):545–51. doi:10.1007/s13277-013-1075-6
95. Mockenhaupt FP, Cramer JP, Hamann L, Stegemann MS, Eckert J, Oh NR,
et al. Toll-like receptor (TLR) polymorphisms in African children: common
TLR-4 variants predispose to severe malaria. Proc Natl Acad Sci U S A (2006)
103(1):177–82. doi:10.1073/pnas.0506803102
96. Garza-Gonzalez E, Bosques-Padilla FJ, Mendoza-Ibarra SI, Flores-Gutierrez
JP, Maldonado-Garza HJ, Perez-Perez GI. Assessment of the toll-like recep-
tor 4 Asp299Gly, Thr399Ile and interleukin-8-251 polymorphisms in the risk
for the development of distal gastric cancer. BMC Cancer (2007) 7(1):70.
doi:10.1186/1471-2407-7-70
97. Ferwerda B, Mccall MB,Verheijen K, Kullberg BJ,Van Der Ven AJ,Van Der Meer
JW, et al. Functional consequences of toll-like receptor 4 polymorphisms. Mol
Med (2008) 14(5–6):346–52. doi:10.2119/2007-00135.Ferwerda
98. Boraska Jelavic T, Barisic M, Drmic Hofman I, Boraska V, Vrdoljak E,
Peruzovic M, et al. Microsatelite GT polymorphism in the toll-like recep-
tor 2 is associated with colorectal cancer. Clin Genet (2006) 70(2):156–60.
doi:10.1111/j.1399-0004.2006.00651.x
99. Li XX, Sun GP, Meng J, Li X, Tang YX, Li Z, et al. Role of toll-like receptor
4 in colorectal carcinogenesis: a meta-analysis. PLoS One (2014) 9(4):e93904.
doi:10.1371/journal.pone.0093904
100. Santini D, Angeletti S, Ruzzo A, Dicuonzo G, Galluzzo S, Vincenzi B, et al.
Toll-like receptor 4 Asp299Gly and Thr399Ile polymorphisms in gastric cancer
of intestinal and diffuse histotypes. Clin Exp Immunol (2008) 154(3):360–4.
doi:10.1111/j.1365-2249.2008.03776.x
101. Zhao X, Kang S, Liu L, Zhang D. Correlation of Asp299Gly and Thr399Ile
polymorphisms in toll-like receptor 4 gene with digestive cancer risk: a meta-
analysis. Biomed Rep (2013) 1(2):294–302. doi:10.3892/br.2012.32
102. Castro FA, Forsti A, Buch S, Kalthoff H, Krauss C, Bauer M, et al. TLR-3 poly-
morphism is an independent prognostic marker for stage II colorectal cancer.
Eur J Cancer (2011) 47(8):1203–10. doi:10.1016/j.ejca.2010.12.011
103. Tsilidis KK, Helzlsouer KJ, Smith MW, Grinberg V, Hoffman-Bolton J, Clipp
SL, et al. Association of common polymorphisms in IL10, and in other genes
related to inflammatory response and obesity with colorectal cancer. Cancer
Causes Control (2009) 20(9):1739–51. doi:10.1007/s10552-009-9427-7
104. Guo Q, Zhu J, Xia B. Polymorphism of CD14 gene but not the mutation of
TLR4 gene is associated with colorectal cancer in Chinese patients. J Gastroen-
terol Hepatol (2006) 21(1 Pt 1):92–7. doi:10.1111/j.1440-1746.2005.04156.x
105. Chen R, Luo FK, Wang YL, Tang JL, Liu YS. LBP and CD14 polymorphisms
correlate with increased colorectal carcinoma risk in Han Chinese. World J
Gastroenterol (2011) 17(18):2326–31. doi:10.3748/wjg.v17.i18.2326
106. Landi S, Gemignani F, Bottari F, Gioia-Patricola L, Guino E, Cambray M,
et al. Polymorphisms within inflammatory genes and colorectal cancer. J Negat
Results Biomed (2006) 5:15. doi:10.1186/1477-5751-5-15
107. Davoodi H, Seow HF. Variant toll-like receptor4 (Asp299Gly and Thr399Ile
alleles) and toll-like receptor2 (Arg753Gln and Arg677Trp alleles) in
colorectal cancer. Iran J Allergy Asthma Immunol (2011) 10(2):91–9. doi:010.
02/ijaai.9199
108. Kutikhin AG, Yuzhalin AE, Volkov AN, Zhivotovskiy AS, Brusina EB. Cor-
relation between genetic polymorphisms within IL-1B and TLR4 genes and
cancer risk in a Russian population: a case-control study. Tumour Biol (2014)
35(5):4821–30. doi:10.1007/s13277-014-1633-6
109. Takahashi K, Sugi Y, Hosono A, Kaminogawa S. Epigenetic regulation of TLR4
gene expression in intestinal epithelial cells for the maintenance of intesti-
nal homeostasis. J Immunol (2009) 183(10):6522–9. doi:10.4049/jimmunol.
0901271
110. Govind CK, Ginsburg D, Hinnebusch AG. Measuring dynamic changes in his-
tone modifications and nucleosome density during activated transcription in
budding yeast. Methods Mol Biol (2012) 833:15–27. doi:10.1007/978-1-61779-
477-3_2
111. Takahashi K, Sugi Y, Nakano K, Tsuda M, Kurihara K, Hosono A, et al. Epige-
netic control of the host gene by commensal bacteria in large intestinal epithe-
lial cells. J Biol Chem (2011) 286(41):35755–62. doi:10.1074/jbc.M111.271007
112. Davie JR. Inhibition of histone deacetylase activity by butyrate. J Nutr (2003)
133(7 Suppl):2485S–93S.
113. Waldecker M, Kautenburger T, Daumann H, Busch C, Schrenk D. Inhibition of
histone-deacetylase activity by short-chain fatty acids and some polyphenol
metabolites formed in the colon. J Nutr Biochem (2008) 19(9):587–93.
doi:10.1016/j.jnutbio.2007.08.002
114. Vamadevan AS, Fukata M, Arnold ET, Thomas LS, Hsu D, Abreu MT. Reg-
ulation of toll-like receptor 4-associated MD-2 in intestinal epithelial cells:
a comprehensive analysis. Innate Immun (2010) 16(2):93–103. doi:10.1177/
1753425909339231
115. Kanzler H, Barrat FJ, Hessel EM, Coffman RL. Therapeutic targeting of innate
immunity with toll-like receptor agonists and antagonists. Nat Med (2007)
13(5):552–9. doi:10.1038/nm1589
116. Akira S. Mammalian toll-like receptors. Curr Opin Immunol (2003) 15(1):5–11.
doi:10.1016/S0952-7915(03)00005-0
117. Mackensen A, Galanos C, Engelhardt R. Treatment of cancer patients with
endotoxin induces release of endogenous cytokines. Pathobiology (1991)
59(4):264–7. doi:10.1159/000163659
118. Engelhardt R, Mackensen A, Galanos C. Phase I trial of intravenously adminis-
tered endotoxin (Salmonella abortus equi) in cancer patients. Cancer Res (1991)
51(10):2524–30.
119. Galluzzi L, Vacchelli E, Eggermont A, Fridman WH, Galon J, Sautes-Fridman
C, et al. Trial watch: experimental toll-like receptor agonists for cancer therapy.
Oncoimmunology (2012) 1(5):699–716. doi:10.4161/onci.20696
120. Mata-Haro V, Cekic C, Martin M, Chilton PM, Casella CR, Mitchell TC. The
vaccine adjuvant monophosphoryl lipid A as a TRIF-biased agonist of TLR4.
Science (2007) 316(5831):1628–32. doi:10.1126/science.1138963
121. Persing DH, Coler RN, Lacy MJ, Johnson DA, Baldridge JR, Hershberg RM,
et al. Taking toll: lipid A mimetics as adjuvants and immunomodulators. Trends
Microbiol (2002) 10(10):s32–7. doi:10.1016/S0966-842X(02)02426-5
122. Krieg AM. Toll-free vaccines? Nat Biotechnol (2007) 25(3):303–5. doi:10.1038/
nbt0307-303
123. Basith S, Manavalan B, Yoo TH, Kim SG, Choi S. Roles of toll-like receptors in
cancer: a double-edged sword for defense and offense. Arch Pharm Res (2012)
35(8):1297–316. doi:10.1007/s12272-012-0802-7
124. D’Agostini C, Pica F, Febbraro G, Grelli S, Chiavaroli C, Garaci E. Antitumour
effect of OM-174 and cyclophosphamide on murine B16 melanoma in differ-
ent experimental conditions. Int Immunopharmacol (2005) 5(7–8):1205–12.
doi:10.1016/j.intimp.2005.02.013
125. De Ridder M, Verovski VN, Chiavaroli C, Van Den Berge DL, Monsaert C,
Law K, et al. The radiosensitizing effect of immunoadjuvant OM-174 requires
cooperation between immune and tumor cells through interferon-gamma
and inducible nitric oxide synthase. Int J Radiat Oncol Biol Phys (2006)
66(5):1473–80. doi:10.1016/j.ijrobp.2006.07.1381
126. Isambert N, Fumoleau P, Paul C, Ferrand C, Zanetta S, Bauer J, et al. Phase
I study of OM-174, a lipid A analogue, with assessment of immunological
response, in patients with refractory solid tumors. BMC Cancer (2013) 13:172.
doi:10.1186/1471-2407-13-172
127. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, et al. Ran-
domized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-
small-cell lung cancer. J Clin Oncol (2005) 23(27):6674–81. doi:10.1200/JCO.
2005.13.011
128. Kroemer G, Zitvogel L, Galluzzi L. Victories and deceptions in tumor immunol-
ogy: Stimuvax. Oncoimmunology (2013) 2(1):e23687. doi:10.4161/onci.23687
Conflict of Interest Statement: The authors declare that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 13 April 2014; paper pending published: 30 April 2014; accepted: 01 July
2014; published online: 15 July 2014.
Citation: Yesudhas D, Gosu V, Anwar MA and Choi S (2014) Multiple roles of toll-like
receptor 4 in colorectal cancer. Front. Immunol. 5:334. doi: 10.3389/fimmu.2014.00334
This article was submitted to Tumor Immunity, a section of the journal Frontiers in
Immunology.
Copyright © 2014 Yesudhas, Gosu, Anwar and Choi. This is an open-access article dis-
tributed under the terms of the Creative Commons Attribution License (CC BY). The
use, distribution or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this journal is cited,
in accordance with accepted academic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Immunology | Tumor Immunity July 2014 | Volume 5 | Article 334 | 10
